GLP1-RA, Kidney Disease
The researchers urged physicians to be vigilant for signs of pancreatitis and to monitor kidney function among people taking GLP-1 medications. Kidney problems can occur without symptoms ...
as well as kidney issues. On the flip side, recent studies show that GLP-1 medications may decrease a person’s risk for cardiovascular disease and dementia. Now, a new study recently published ...
Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than ...
GLP-1 agonists also were tied to 12% reduced risk for acute kidney injury and 3% lower risk ... and a stabilizing effect on endothelial function, which may be driving cardiovascular benefits ...
Previous studies have found that SGLT2 inhibitors appear to lower HbA1c less in patients with worse kidney function.” “GLP-1 agonists appear to be less affected by this interaction,” he added.
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback